Sponsored by: Investment Center

Something new in your business?  Click here to submit your business press release

Chamber Corner | Main Street News | Job Hunt | Classifieds | Calendar | Illinois Lottery 

Futures advance after three-day rally; data on tap

Send a link to a friend  Share

[December 22, 2014]  By Chuck Mikolajczak
 
 NEW YORK (Reuters) - U.S. stock index futures advanced on Monday, after the S&P 500 notched its best weekly performance in almost two months, ahead of data on the housing market.

* Brent crude <LCOc1> hit a high of $62.97 and WTI crude rose to as much as $58.53 amid investor confidence there would be no substantial price loss in the run-up to the new year. Brent last traded down 21 cents at $61.17 while U.S. crude was last off 0.7 percent at $56.74 after Saudi Arabia indicated it could increase its output. [O/R]

* The benchmark S&P index <.SPX> rose 3.4 percent last week, boosted by a 5 percent jump over three sessions, after the U.S. Federal Reserve said it would take a "patient" approach toward raising interest rates and oil prices appeared to stabilize. The S&P energy index <.SPNY> surged nearly 10 percent for the week.

* Investors await existing home sales data, due out at 10:00 a.m.. Expectations are for a decline of 1 percent.

* Trading volume is expected to be light this week due to the Christmas holiday, which could increase volatility. U.S. equity markets will operate a shortened session on Wednesday and be closed on Thursday.

* Gilead Sciences <GILD.O> lost 10.2 percent to $97.35 in premarket trade. Express Scripts, the nation's largest pharmacy benefit manager, has lined up a cheaper price from AbbVie Inc <ABBV.N> on its newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead's treatments.

* BioCryst Pharmaceuticals <BCRX.O> jumped 5.3 percent to $11.75 in premarket trade after the U.S. Food and Drug Administration approved its intravenous flu drug.

* Achillion Pharmaceuticals Inc <ACHN.O> said it would test a combination of two of its experimental hepatitis C drugs which showed promise in separate studies. Its shares rose 16.1 percent to $16.50 before the opening bell with over 2.2 million shares changing hands, the most actively traded issue on the Nasdaq.

[to top of second column]

* Caesars Entertainment Corp <CZR.O> said it would merge with affiliate Caesars Acquisition <CACQ.O> in an all-stock deal. Caesars Entertainment gained 9.7 percent to $14.80 in light premarket trade while Caesars Acquisition rose 11 percent to $10.50.

Futures snapshot at 8:11 a.m. EST:

* S&P 500 e-minis <ESc1> were up 5.75 points, or 0.28 percent, with 91,013 contracts changing hands.

* Nasdaq 100 e-minis <NQc1> were up 2.75 points, or 0.06 percent, in volume of 17,847 contracts.

* Dow e-minis <1YMc1> were up 60 points, or 0.34 percent, with 13,465 contracts changing hands.

(Editing by Bernadette Baum)

[© 2014 Thomson Reuters. All rights reserved.]

Copyright 2014 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Back to top